THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
申请人:Lemieux Rene M.
公开号:US20150031627A1
公开(公告)日:2015-01-29
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
[EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS MÉTHODES D'UTILISATION
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2015010297A1
公开(公告)日:2015-01-29
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
[EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET UTILISATION DE CEUX-CI
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2015010626A1
公开(公告)日:2015-01-29
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.
[EN] COMPOUNDS AND THEIR USES AS CD38 INHIBITORS<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE CD38
申请人:NANJING IMMUNOPHAGE BIOTECH CO LTD
公开号:WO2022228496A1
公开(公告)日:2022-11-03
Provided are compounds of Formula I which can be used as CD38 inhibitors; methods for the production of the compounds; pharmaceutical compositions comprising the compounds; as well as uses and methods for treating a disease mediated by CD38 by administering the compounds.
PHARMACEUTICAL COMPOSITION USEFUL IN INHIBITING IDH1
申请人:Les Laboratoires Servier SAS
公开号:EP3985001A1
公开(公告)日:2022-04-20
Provided is a pharmaceutical composition useful in treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising a compound of the following formula: